Compare Stocks: IMRX, REPL, GLUE, and MGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$15.87 +5.6%	$20.27	$4.30 ▼ $25.77	$1.35B	1.59	1.37 million shs	187,739 shs
IMRX Immuneering	$5.22 +3.9%	$4.66	$3.25 ▼ $10.08	$337.52M	0.43	1.39 million shs	98,534 shs
MGTX MeiraGTx	$14.51 +4.5%	$12.28	$6.62 ▼ $15.35	$1.39B	1.23	707,559 shs	162,182 shs
REPL Replimune Group	$15.14 -2.8%	$10.90	$1.50 ▼ $15.70	$1.28B	0.88	4.96 million shs	1.04 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-2.28%	-4.63%	-38.80%	-19.41%	+229.61%
IMRX Immuneering	-3.64%	+4.79%	+8.41%	+0.20%	+43.71%
MGTX MeiraGTx	+0.87%	+6.44%	+11.66%	+44.99%	+74.28%
REPL Replimune Group	+6.49%	+14.14%	+52.30%	+201.94%	+192.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$15.87 +5.6%	$20.27	$4.30 ▼ $25.77	$1.35B	1.59	1.37 million shs	187,739 shs
IMRX Immuneering	$5.22 +3.9%	$4.66	$3.25 ▼ $10.08	$337.52M	0.43	1.39 million shs	98,534 shs
MGTX MeiraGTx	$14.51 +4.5%	$12.28	$6.62 ▼ $15.35	$1.39B	1.23	707,559 shs	162,182 shs
REPL Replimune Group	$15.14 -2.8%	$10.90	$1.50 ▼ $15.70	$1.28B	0.88	4.96 million shs	1.04 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-2.28%	-4.63%	-38.80%	-19.41%	+229.61%
IMRX Immuneering	-3.64%	+4.79%	+8.41%	+0.20%	+43.71%
MGTX MeiraGTx	+0.87%	+6.44%	+11.66%	+44.99%	+74.28%
REPL Replimune Group	+6.49%	+14.14%	+52.30%	+201.94%	+192.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$28.50	79.63% Upside
IMRX Immuneering	3.00	Buy	$17.50	234.99% Upside
MGTX MeiraGTx	3.00	Buy	$26.17	80.35% Upside
REPL Replimune Group	2.60	Moderate Buy	$11.86	-21.68% Downside

Current Analyst Ratings Breakdown

Latest IMRX, REPL, GLUE, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $27.00
8/13/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/11/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $28.00
8/7/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$12.00
8/7/2026	GLUE Monte Rosa Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$31.00 ➝ $27.00
8/7/2026	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$29.00 ➝ $27.00
8/7/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $20.00
8/6/2026	IMRX Immuneering	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$28.73M	47.12	N/A	N/A	$3.58 per share	4.43
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
MGTX MeiraGTx	$81.39M	17.12	N/A	N/A	($0.07) per share	-207.27
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
IMRX Immuneering	-$56.03M	-$1.04	N/A	N/A	N/A	N/A	-27.15%	-25.75%	N/A
MGTX MeiraGTx	-$114.20M	$0.71	20.39	N/A	N/A	19.87%	283.85%	29.39%	N/A
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-139.22%	-84.42%	11/5/2026 (Estimated)

Latest IMRX, REPL, GLUE, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/5/2026	Q2 2026	IMRX Immuneering	-$0.2643	-$0.27	-$0.0057	-$0.27	N/A	N/A
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
IMRX Immuneering	N/A	19.47	19.47
MGTX MeiraGTx	0.46	3.76	3.76
REPL Replimune Group	0.63	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
IMRX Immuneering	67.65%
MGTX MeiraGTx	67.48%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.40%
IMRX Immuneering	14.90%
MGTX MeiraGTx	7.40%
REPL Replimune Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable
IMRX Immuneering	60	64.70 million	55.06 million	Not Optionable
MGTX MeiraGTx	300	96.04 million	88.94 million	Optionable
REPL Replimune Group	210	84.03 million	79.49 million	Optionable

IMRX, REPL, GLUE, and MGTX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 18 at 4:56 PM | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Up 5.2% - What's Next?

August 18 at 12:19 PM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 18 at 10:39 AM | globenewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

August 18 at 10:13 AM | prnewswire.com

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

August 18 at 10:11 AM | globenewswire.com

Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL

August 18 at 4:39 AM | marketbeat.com

Head-To-Head Contrast: Replimune Group (NASDAQ:REPL) & Arcus Biosciences (NYSE:RCUS)

August 18 at 3:58 AM | americanbankingnews.com

Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL

August 17 at 4:46 PM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

August 17 at 12:00 PM | globenewswire.com

REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

August 17 at 11:16 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 15, 2026 | globenewswire.com

Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

August 14, 2026 | marketbeat.com

Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14, 2026 | finanznachrichten.de

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

August 14, 2026 | globenewswire.com

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

August 14, 2026 | globenewswire.com

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14, 2026 | globenewswire.com

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

August 13, 2026 | finance.yahoo.com

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL

August 13, 2026 | businesswire.com

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Replimune Group, Inc. Investors - Contact Kirby McInerney LLP by October 5, 2026

August 13, 2026 | globenewswire.com

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

August 13, 2026 | prnewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

August 13, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMRX, REPL, GLUE, and MGTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$15.87 +0.84 (+5.56%)

As of 10:32 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Immuneering NASDAQ:IMRX

$5.22 +0.19 (+3.86%)

As of 10:32 AM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

MeiraGTx NASDAQ:MGTX

$14.51 +0.62 (+4.46%)

As of 10:31 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Replimune Group NASDAQ:REPL

$15.14 -0.44 (-2.83%)

As of 10:32 AM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMRX, REPL, GLUE, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMRX, REPL, GLUE, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMRX, REPL, GLUE, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMRX, REPL, GLUE, and MGTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Immuneering NASDAQ:IMRX

MeiraGTx NASDAQ:MGTX

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMRX, REPL, GLUE, and MGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMRX, REPL, GLUE, and MGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMRX, REPL, GLUE, and MGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMRX, REPL, GLUE, and MGTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Immuneering NASDAQ:IMRX

MeiraGTx NASDAQ:MGTX

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools